On-demand hyoscine butylbromide for the treatment of self-reported functional cramping abdominal pain

Scandinavian Journal of Gastroenterology

Volumn 48, Issue 8, 2013, Pages 926-935

  Lacy, Brian E ^a   Wang, Fei ^b   Bhowal, Sujata ^b   Schaefer, Eckhard ^c  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^c BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Abdominal cramps; Abdominal pain; Anticholinergic agents; Antispasmodic agents; Functional colonic diseases; Hyoscine butylbromide

Indexed keywords

ACETYLSALICYLIC ACID; IBUPROFEN; MULTIVITAMIN; NAPROXEN; PARACETAMOL; PLACEBO; SCOPOLAMINE BUTYL BROMIDE;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADULT; ANALGESIA; ARTICLE; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PAIN ASSESSMENT; PATIENT SATISFACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SELF MEDICATION; SELF REPORT; SPRAIN; TREATMENT DURATION;

ADOLESCENT; ADULT; AGED; BUTYLSCOPOLAMMONIUM BROMIDE; COLIC; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PAIN MEASUREMENT; PILOT PROJECTS; RECURRENCE; ROC CURVE; SELF REPORT; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84880416561     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2013.804117     Document Type: Article

References (22)

1. Pomeroy AR, Rand MJ. Anticholinergic effects and passage through the intestinal wall of N-butyl hyoscine bromide. J Pharm Pharmacol 1969;21:180-7.
2. Bommelaer G, Poynard T, Le Pen C, Gaudin AF, Maurel F, Priol G, et al. Prevalence of irritable bowel syndrome (IBS) and variability of diagnostic criteria. Gastroenterol Clin Biol 2004;28:554-61.
3. Quigley EMM, Locke GR, Mueller-Lissner S, Paulo LG, Tytgat GN, Helfrich I, et al. Prevalence and management of abdominal cramping and pain: a multinational survey. Aliment Pharmacol Ther 2006;24:411-19.
4. Sandler RS, Stewart WF, Liberman JN, Ricci JA, Zorich NL. Abdominal pain, bloating, and diarrhea in the United States: prevalence and impact. Dig Dis Sci 2000;45:1166-71.
5. Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Mueller-Lissner SA. Functional bowel disorders and functional abdominal pain. Gut 1999; 45:43-7.
6. Nigam P, Kapoor KK, Rastog CK, Kumar A, Gupta AK. Different therapeutic regimens in irritable bowel syndrome. J Assoc Physicians India 1984;32:1041-4.
7. Ritchie JA, Truelove SC. Treatment of irritable bowel syndrome with lorazepam, HBB butylbromide and ispaghula husk. Br Med J 1979;1:376-8.
8. Ford AC, Talley NJ, Spiegel BM, Foxx-Orenstein AE, Schiller L, Quigley EM, et al. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ 2008;337: a2313. Erratum in: BMJ.2009;338:b1881.
9. Jailwala J, Imperiale TF, Kroenke K. Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomised, controlled trials. Ann Intern Med 2000;133: 136-47.
10. Poynard T, Regimbeau C, Benhamou Y. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2001;15:355-61.
11. Quartero AO, Meineche-Schmidt V, Muris J, Rubin G, de Wit N. Bulking agents, antispasmodic and antidepressant medication for the treatment of irritable bowel syndrome (review). Cochrane Database Syst Rev 2005;2:CD0033460.
12. Veldhuyzen van Zanten SJ, Talley NJ, Bytzer P, Klein KB, Whorwell PJ, Zinsmeister AR. Design of treatment trials for functional gastrointestinal disorders. Gut 1999;45:II69-77.
13. Irvine EJ, Whitehead WE, Chey WD, Matsueda K, Shaw M, Talley NJ, et al. Design of treatment trials for functional gastrointestinal disorders. Gastroenterology 2006;130:1538-51.
14. Mueller-Lissner S, Tytgat GN, Paulo LG, Quigley EMM, Bubeck J, Peil H, et al. Placebo-and paracetamol-controlled study on the efficacy and tolerability of HBB butylbromide in the treatment of patients with recurrent crampy abdominal pain. Aliment Pharmacol Ther 2006;23:1741-8.
15. Schaefer E, Ewe K. Treatment of irritable bowel syndrome: efficacy and tolerance of Buscopan plus, Buscopan, paracetamol and placebo in ambulatory patients with IBS. Fortschr Med 1990;108:488-92.
16. Tytgat GN. Hyoscine butylbromide: a review of its use in the treatment of abdominal cramping and pain. Drugs 2007;67: 1343-57.
17. Drossman DA, Richter JE, Talley NJ, Thompson WG, Corraziari E, Whitehead WE. The functional gastrointestinal disorders: diagnosis, pathophysiology, and treatment-a multinational consensus. Boston: Little, Brown; 1994. pp 370.
18. Manning AP, Thompson WG, Heaton KE, Morris AF. Towards positive diagnosis of the irritable bowel. Br Med J 1978;2:653-4.
19. Evangelista S. Quaternary ammonium derivatives as spasmolytics for irritable bowel syndrome. Curr Pharm Des 2004; 10:3561-8.
20. Ge Z, Yuan Y, Zhang S, Hou X, Wang J, Cai J, et al. Efficacy and tolerability of two oral hyoscine butylbromide formulations in Chinese patients with recurrent episodes of selfreported gastric or intestinal spasm-like pain. Int J Clin Pharmacol Ther 2011;49:198-205.
21. Mertz HR. Irritable bowel syndrome. N Engl J Med 2003; 349:2136-46.
22. Hungin APS, Whorwell PJ, Tack J, Mearin F. The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 patients. Aliment Pharmacol Ther 2003;17:643-50.